Use Via Early Access to Ixazomib (UVEA-IXA) Study: Effectiveness and Safety of Ixazomib-based Therapy in Relapsed/Refractory Multiple Myeloma Outside of the Clinical Trial Setting

In multiple myeloma (MM), improving our understanding of routine clinical practice and the effectiveness of agents outside of clinical trials is important. TOURMALINE-MM1 data resulted in approval of ixazomib for MM patients who have received ≥1 prior therapy.

Source: Clinical Lymphoma, Myeloma and Leukemia - October 13, 2023 Category: Hematology Authors: Heinz Ludwig, Karthik Ramasamy, Mar ía-Victoria Mateos, Bhuvan Kishore, Varga Gergely, Miriam Ladicka, Alessandra Ori, Lucia Simoni, Nawal Bent-Ennakhil, Dawn Marie Stull, François Gavini, Evangelos Terpos, Roman Hájek Tags: Original Study Source Type: research